{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T16:35:58Z","timestamp":1740155758301,"version":"3.37.3"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2015,2,24]],"date-time":"2015-02-24T00:00:00Z","timestamp":1424736000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Clin Oncol"],"published-print":{"date-parts":[[2015,4]]},"DOI":"10.1038\/nrclinonc.2015.37","type":"journal-article","created":{"date-parts":[[2015,2,24]],"date-time":"2015-02-24T11:03:12Z","timestamp":1424775792000},"page":"194-196","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["New standard of care\u2014HPV testing for cervical cancer screening"],"prefix":"10.1038","volume":"12","author":[{"given":"Philip E.","family":"Castle","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,2,24]]},"reference":[{"key":"BFnrclinonc201537_CR1","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1038\/bjc.2014.362","volume":"111","author":"S Vaccarella","year":"2014","unstructured":"Vaccarella, S.  et al. 50 years of screening in the Nordic countries: quantifying the effects on cervical cancer incidence. Br. J. Cancer 111, 965\u2013969 (2014).","journal-title":"Br. J. Cancer"},{"key":"BFnrclinonc201537_CR2","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1002\/cncr.20064","volume":"100","author":"SS Wang","year":"2004","unstructured":"Wang, S. S., Sherman, M. E., Hildesheim, A., Lacey, J. V. Jr & Devesa, S. Cervical adenocarcinoma and squamous cell carcinoma incidence trends among white women and black women in the United States for 1976\u20132000. Cancer 100, 1035\u20131044 (2004).","journal-title":"Cancer"},{"key":"BFnrclinonc201537_CR3","doi-asserted-by":"publisher","unstructured":"Wright, T. C.  et al. Primary cervical cancer screening with human papillomavirus: end of study results from the ATHENA study using HPV as the first-line screening test. Gynecol. Oncol. \n                    http:\/\/dx.doi.org\/10.1016\/j.ygyno.2014.11.076\n                    \n                   (2015).","DOI":"10.1016\/j.ygyno.2014.11.076"},{"key":"BFnrclinonc201537_CR4","doi-asserted-by":"publisher","unstructured":"Huh, W. K.  et al. Use of primary high-risk human papillomavirus testing for cervical cancer screening: interim clinical guidance. Gynecol. Oncol. \n                    http:\/\/dx.doi.org\/10.1016\/j.ygyno.2014.12.022\n                    \n                   (2015).","DOI":"10.1016\/j.ygyno.2014.12.022"},{"key":"BFnrclinonc201537_CR5","doi-asserted-by":"publisher","first-page":"a1754","DOI":"10.1136\/bmj.a1754","volume":"337","author":"J Dillner","year":"2008","unstructured":"Dillner, J.  et al. Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study. BMJ 337, a1754 (2008).","journal-title":"BMJ"},{"key":"BFnrclinonc201537_CR6","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1016\/S0140-6736(13)62218-7","volume":"383","author":"G Ronco","year":"2014","unstructured":"Ronco, G.  et al. Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. Lancet 383, 524\u2013532 (2014).","journal-title":"Lancet"},{"key":"BFnrclinonc201537_CR7","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1097\/AOG.0000000000000632","volume":"125","author":"W Kinney","year":"2015","unstructured":"Kinney, W.  et al. Increased cervical cancer risk associated with screening at longer intervals. Obstet. Gynecol. 125, 311\u2013315 (2015).","journal-title":"Obstet. Gynecol."},{"key":"BFnrclinonc201537_CR8","doi-asserted-by":"publisher","first-page":"147","DOI":"10.3322\/caac.21139","volume":"62","author":"D Saslow","year":"2012","unstructured":"Saslow, D.  et al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. CA Cancer J. Clin. 62, 147\u2013172 (2012).","journal-title":"CA Cancer J. Clin."},{"issue":"Suppl. 1","key":"BFnrclinonc201537_CR9","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1097\/LGT.0b013e318287d329","volume":"17","author":"LS Massad","year":"2013","unstructured":"Massad, L. S.  et al. 2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. J. Low. Genit. Tract. Dis. 17 (Suppl. 1), S1\u2013S27 (2013).","journal-title":"J. Low. Genit. Tract. Dis."},{"key":"BFnrclinonc201537_CR10","doi-asserted-by":"publisher","first-page":"dju423","DOI":"10.1093\/jnci\/dju423","volume":"107","author":"C Bergeron","year":"2015","unstructured":"Bergeron, C.  et al. Informed cytology for triaging HPV-positive women: substudy nested in the NTCC randomized controlled trial. J. Natl Cancer Inst. 107, dju423 (2015).","journal-title":"J. Natl Cancer Inst."}],"container-title":["Nature Reviews Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nrclinonc.2015.37.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrclinonc.2015.37","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrclinonc.2015.37.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T03:28:55Z","timestamp":1684466935000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrclinonc.2015.37"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2,24]]},"references-count":10,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,4]]}},"alternative-id":["BFnrclinonc201537"],"URL":"https:\/\/doi.org\/10.1038\/nrclinonc.2015.37","relation":{},"ISSN":["1759-4774","1759-4782"],"issn-type":[{"type":"print","value":"1759-4774"},{"type":"electronic","value":"1759-4782"}],"subject":[],"published":{"date-parts":[[2015,2,24]]},"assertion":[{"value":"24 February 2015","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"P.E.C. has received commercial human papillomavirus tests for research at a reduced or no cost from Arbor Vita Corporation, BD Diagnostics, mtm laboratories, NorChip, QIAGEN, and Roche. P.E.C. has been compensated financially as a member of a Merck Data and Safety Monitoring Board for HPV vaccines, and has been a paid consultant for BD Diagnostics, Cepheid, ClearPath, GE Healthcare, Gen-Probe\/Hologic, Genticel, Guided Therapeutics, Inovio Pharmaceuticals, Roche, and Teva Pharmaceuticals. P.E.C. has also received honouraria as a speaker for Cepheid and Roche.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}